Captopril and enalaprilat decrease antioxidant defences in human endothelial cells and are unable to protect against apoptosis

Cell Biology International

Volumn 27, Issue 10, 2003, Pages 825-830

  Mailloux, Agnès ^a   Deslandes, Benjamin ^a   Vaubourdolle, Michel ^a   Baudin, Bruno ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIPID PEROXIDATION; NECROSIS; UMBILICAL VEIN;

EID: 0141788675     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1065-6995(03)00162-8     Document Type: Article

References (52)

1. Al-Shabanad O., Mansour M., Nagi H., Al-Sawaf H., Al-Bekairi A. Does captopril scavenge superoxide radical? Med Sci Res. 25:1997;841-843.
2. Al-Shabanad O., Mansour M., El-Khasef H., Al-Bekairi A. Captopril ameliorates myocardial and haematological toxicities induced by adriamycin. Biochem Mol Biol Int. 45:1998;419-427.
3. Ambrosioni E., Bachelli S., Degli Esposti D., Borghi C. ACE-inhibitors and atherosclerosis. Eur J Epidemiol. 8:(Suppl 1):1992;129-133.
4. Aruoma O., Akanumu D., Cecchini R., Hariwell B. Evaluation of the ability of the angiotensin-converting enzyme inhibitor captopril to scavenge reactive oxygen species. Chem-Biol Interact. 77:1991;303-314.
5. Bartosz M., Kedziora J., Bartosz G. Antioxidant and pro-oxidant properties of captopril and enalapril. Free Radic Biol Med. 23:1997;729-735.
6. Baudin B., Drouet L. In vitro interactions between ramiprilat and angiotensin I-converting enzyme in endothelial cells. J Cardiovasc Pharmacol. 14:(Suppl 4):1989;S37-S42.
7. Baudin B. Toxicité endothéliale des chimiothérapies anti-cancéreuses. Sang Thrombose et Vaisseaux. 7:1995;175-183.
8. Baudin B., Bénéteau-Burnat B., Giboudeau J. Cytotoxicity of amiodarone in cultured human endothelial cells. Cardiovasc Drugs Ther. 10:1996;557-560.
9. Baudin B., Bérard M., Carrier J.L., Legrand Y., Drouet L. Vascular origin determines angiotensin-converting enzyme expression in endothelial cells. Endothelium. 5:1997;73-84.
10. Baudin B. New aspects on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med. 40:2002;256-265.
11. Benzie I., Tomlison B. Antioxidant power of angiotensin-converting enzyme inhibitors in vitro. Br J Clin Pharmacol. 45:1998;168-169.
12. Brown N., Vaughan D. Angiotensin-converting enzyme inhibitors. Circulation. 97:1998;1411-1420.
13. Cannon R. Potential mechanisms for the effect of angiotensin-converting enzyme inhibitors on endothelial dysfunction: the role of nitric oxide. Am J Cardiol. 82:1998;8S-10S.
14. De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Lipidol. 11:2000;9-23.
15. De Cavanagh E., Inserra F., Ferder L., Romano L., Ercole L., Fraga C. Superoxide-dismutase and glutathione-peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett. 361:1995;22-24.
16. De Cavanagh E., Inserra F., Ferder L., Fraga C. Enalapril and captopril enhance glutathione-dependent antioxidant defences in mouse tissues. Am J Physiol. 278:2000;R572-R577.
17. De Cavanagh E., Inserra F., Toblli J., Stella I., Fraga C., Ferder L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension. 38:2001;1130-1136.
18. Doroshow J., Locker G., Ifrim L., Myers C. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest. 68:1981;1053-1064.
19. Drexler H. Endothelial dysfunction in heart failure and potential for reversal by ACE inhibition. Br Heart J. 72:1994;11-14.
20. Drexler H. Endothelial dysfunction: clinical implications. ProgCardiovasc Dis. 39:1997;287-324.
21. Filippatos G., Uhal B.D. Blockade of apoptosis by ACE inhibitors and angiotensin receptor antagonists. Curr Pharm Des. 9:2003;707-714.
22. Fisher S., MacLean A., Liu M., Kalirai B., Keshavjee S. Inhibition of angiotensin-converting enzyme by captopril: a novel approach to reduce ischemia-reperfusion injury after transplantation. J Thorac Cardiovasc Surg. 120:2000;573-580.
23. Hernandez A., Barberi L., Ballerio R., Testini A., Ferioli R., Bolla M., et al. Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. Atherosclerosis. 137:1998;71-76.
24. Jacobsson L., Persson K., Aberg G., Andersson R., Karlberg B., Olsson A. Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic mini-pigs. J Cardiovasc Pharmacol. 24:1994;670-677.
25. Jaffe E., Nachman R., Becker C., Minick C. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 52:1973;2745-2746.
26. Kang Y., Zhou Z.X., Wang G.W., Buridi A., Klein J. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem. 275:2000;13690-13698.
27. Keizer H., Pinedo H., Schuurnis G., Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 47:2000;219-231.
28. Kowala M., Valentine M., Recce R., Beyer S., Goller N., Durham S., et al. Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril. J Cardiovasc Pharmacol. 32:1998;29-38.
29. Kuo P., Abe K., Schroeder R. Interleukin-1-induced nitric oxide production modulates glutathione synthesis in cultured rat hepatocytes. Am J Physiol. 271:1996;C851-C862.
30. Lazo J. Endothelial injury caused by antineoplastic agents. Biochem Pharmacol. 35:1986;1919-1923.
31. Lefrak E., Pitha J., Rosenheim S., Gottleib J. A clinicopathologic analysis of adriamycin cardio-toxicity. Cancer. 32:1973;302-314.
32. Lock R., Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res. 56:1996;4006-4012.
33. Maeda A., Honda M., Kuramochi T., Tanaka K., Takanabe T. An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Clin Exp Pharmacol Physiol. 24:1997;720-726.
34. Mailloux A., Grenet K., Bruneel A., Bénéteau-Burnat B., Vaubourdolle M., Baudin B. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol. 80:2001;442-449.
35. Mak I., Komarov A., Wagner T., Stafford R., Dickens B., Weglicki W. Enhanced NO production during Mg deficiency and its role in mediating red blood cell glutathione loss. Am J Physiol. 271:1996;C385-C390.
36. Mancini G. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin Invest Med. 23:2000;144-161.
37. Moellering D., Mc Andrew J., Pattel R., Forman H., Mulcahy R., Jo H., et al. The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells: a role of gamma-glutamylcysteine-synthetase and gamma-glutamyl-transpeptidase. FEBS Lett. 448:1999;292-296.
38. Odaka C., Mizuochi T. Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clin Exp Immunol. 121:2000;515-522.
39. Paglia D., Valentine W. Studies on the qualitative and quantitative characterization of erythrocyte glutathione-peroxidase. J Lab Clin Med. 70:1967;158-159.
40. Pfeffer M., Braunwald E., Moye L., Basta L., Brown E., Cuddy T., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med. 327:1992;669-677.
41. Pieper G., Siebeneich W. Temocapril, an angiotensin-converting enzyme inhibitor, protects against diabetes-induced endothelial dysfunction. Eur J Pharmacol. 403:2000;129-132.
42. Richer C., Giroux B., Plouin P., Maarek B., Giudicelli J. Captopril: pharmacokinetics, antihypertensive and biological effects inhypertensive patients. Br J Clin Pharmacol. 17:1984;243-250.
43. Sacco G., Bigioni M., Evangelista S., Goso C., Manzini S., Maggi C. Cardio-protective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardio-toxicity in the rat. Eur J Pharmacol. 414:2001;71-78.
44. Scrobohaci M.L., Drouet L., Monem-Mansi A., Devergie A., Baudin B., D'Agay M.F., et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 63:1991;509-519.
45. Sinha B., Karki A., Batist G., Cowan K., Myers C. Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol. 36:1987;793-796.
46. Stehouwer C., Lambert J., Donker A., Van Hinsberg V. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 34:1997;55-68.
47. Effect of enalapril on mortality and the development heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
48. Tokudome T., Mizushige K., Noma T., Manabe K., Murakami K., Tsuji T., et al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol. 36:2000;361-368.
49. Uhal B.D., Gidea C., Bargout R., Bifero A., Ibarra-Sunga O., Papp M., et al. Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol. 275:1998;L1013-L1017.
50. Unverferth D., Leier C., Balcerzak S., Hamlin L. Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. Am J Cardiol. 56:1985;157-161.
51. Van Vleet J., Ferrans V., Weirich W. Cardiac disease induced by chronic adriamycin administration in dogs and evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol. 99:1980;13-42.
52. Yin X., Wu H., Chen Y., Kang Y. Induction of antioxidants by adriamycin in mouse heart. Biochem Pharmacol. 56:1998;87-93.